t84.66
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 11, 2005 (NCT00645710)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CEACAM5 binding agent
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109370 ↗
- ChEMBLCHEMBL2109369 ↗
Also known as
- 90y-ct84.66
- t84.66
- t84.66
- y90 anti-cea monoclonal antibody ct84.66
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00738452 | Phase 1 | Aug 6, 2008 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00647153 | N/A | May 1, 2006 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00645710 | Phase 1/Phase 2 (Phase 2) | Feb 11, 2005 | City of Hope National Medical Center |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 3 | 3 | 3 | 2005 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2006 |
2 organizations
Page 1 / 1